Core Viewpoint - The collaboration between Insilico Medicine and a global independent pharmaceutical company, Sviat, is a significant multi-year R&D partnership valued at up to $888 million, focusing on challenging oncology targets and the development of new therapeutic drugs [1] Group 1: Partnership Details - The partnership will leverage Insilico's proprietary AI platform, Pharma.AI, to identify and develop potential drug candidates [1] - Insilico is eligible for an upfront payment of up to $32 million and milestone payments related to recent R&D achievements [1] - Sviat will co-fund the R&D costs and lead subsequent clinical validation and commercialization processes [1] Group 2: Statements from Executives - Christophe Thurieau, Executive Director at Sviat, emphasized the commitment to using cutting-edge technology to address unmet medical needs and benefit patients [1] - Alex Zhavoronkov, CEO of Insilico, expressed excitement about the collaboration, highlighting the recognition of the company's AI drug development capabilities and the potential for AI to enhance the drug development process [1]
英硅智能(03696)与施维雅达成价值8.88亿美元的多年期抗肿瘤药物研发合作